Keros Therapeutics, Inc. (KROS) Stock Price & Analysis
Keros Therapeutics, Inc. (KROS) rose 1.89% to USD 11.32 as of September 8, 2026 at 06:23 UTC, according to Nexqual real-time market data.
KROS last closed at USD 11.32; the session ranged USD 11.02–11.4 on volume of 65,636 shares. Market capitalization is —, with a 52-week range of USD 9.69–22.55 (NGM). Source: Nexqual, September 8, 2026 at 06:23 UTC.
Key Statistics (as of September 8, 2026 at 06:23 UTC)
| Price | USD 11.32 |
|---|---|
| Change | ▲ 1.89% (up) |
| Previous Close | USD 11.32 |
| Open | USD 11.32 |
| Day Range | USD 11.02 – 11.4 |
| 52-Week Range | USD 9.69 – 22.55 |
| Volume | 65,636 shares |
| Market Cap | — |
| Exchange | NGM |
Technical Analysis (KROS)
Nexqual's technical model rates KROS "STRONG BUY" based on 5 bullish and 0 bearish signals across 128 daily candles, as of September 8, 2026 at 06:23 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 55.95 (neutral) |
| vs SMA50 | Above (USD 10.81) |
| MACD | 0.16 (positive) |
From Keros Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-04)
Key Strengths & Strategy (as disclosed to the SEC)
- We intend to also opportunistically evaluate strategic collaborations to maximize the potential commercial value of our product candidates and discovery programs. • Leverage our proprietary discovery approach and knowledge base to develop new therapeutics .
- Phase 3 Clinical Trial Design Our Preclinical Pipeline Our Proprietary Discovery Approach We believe, based on our previous experience with ActRII ligand traps using endogenous and wild-type sequences, that observations in preclinical rodent models have the potential to translate to humans in the clinic.
- We have developed a proprietary library of ActRII ligand traps by combining sequences from ActRIIA and ActRIIB.
Partnerships
- In December 2024, we entered into an exclusive license agreement with Takeda Pharmaceuticals U.S.A., Inc., or Takeda, to further develop, manufacture and commercialize elritercept worldwide outside of mainland China, Hong Kong and Macau, which became effective on January 16, 2025.
- The dosing of the first patient triggered a $10 million milestone payment to us under the license agreement with Takeda.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ZNTL | Zentalis Pharmaceuticals, Inc. | USD 3.99 | ▲ 5.84% |
| ORIC | Oric Pharmaceuticals, Inc. | USD 12.86 | ▼ 2.06% |
| INBX | Inhibrx Biosciences, Inc. | USD 121.17 | ▼ 3.04% |
| KYMR | Kymera Therapeutics, Inc. | USD 117.39 | ▼ 1.05% |
| PCVX | Vaxcyte, Inc. | USD 61.16 | ▼ 0.68% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 06:23 UTC. This page is informational and not investment advice.